|
Combination products (medical products that combine drugs, medical devices, and/or biological products) are increasingly incorporating cutting-edge, novel technologies that hold great promise for advancing patient care. Drug-eluting stents and inhaled insulin are two breakthrough new products approved since the Office of Combination Products was established. Other combination products anticipated include novel |
|
drug-delivery systems, drug-device combinations that are tailored to the way an individual's genetic inheritance affects the body's response to drugs, nanotechnology, gene therapy systems and many other diagnostic and therapeutic treatments. The Office of Combination Products expects these products to continue to become more complicated as new technologies emerge and existing technologies mature.
|
|